T-cell immunity generated by recombinant adenovirus vaccines

Expert Review of Vaccines

Volumn 6, Issue 3, 2007, Pages 347-356

  Teng, Chih Yang ^a   Millar, James B ^a   Grinshtein, Natalie ^a   Bassett, Jennifer ^a   Finn, Jonathan ^a   Bramson, Jonathan L ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

Adenovirus; Immunology; T lymphocyte; Vaccine

Indexed keywords

ADENOVIRUS VECTOR; GAMMA INTERFERON; RECOMBINANT HUMAN ADENOVIRUS 5 VACCINE; UNCLASSIFIED DRUG; VIRUS VACCINE;

ANTIBODY PRODUCTION; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; B LYMPHOCYTE; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL POPULATION; CELLULAR IMMUNITY; CYTOKINE RELEASE; DRUG MECHANISM; EBOLA VIRUS; ENZYME LINKED IMMUNOSPOT ASSAY; GENE DELETION; GENE EXPRESSION; GENE MUTATION; GENE REPLACEMENT THERAPY; GENE SEQUENCE; HEMAGGLUTINATION; HEPATITIS C VIRUS; HUMAN ADENOVIRUS 5; IMMUNIZATION; IMMUNOBIOLOGY; IMMUNOGENICITY; INFLUENZA VIRUS; MEMORY T LYMPHOCYTE; MOUSE STRAIN; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SIMIAN IMMUNODEFICIENCY VIRUS; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; VIRUS GENE; VIRUS INFECTION; VIRUS RECOMBINANT;

ADENOVIRIDAE; ANIMALS; ANTIGEN PRESENTATION; CANCER VACCINES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; GENETIC VECTORS; HUMANS; VACCINES, SYNTHETIC; VIRAL VACCINES;

EID: 34250325442     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.6.3.347     Document Type: Review

References (118)

1. Lambert PH, Liu M, Siegrist CA. Can successful vaccines teach us how to induce efficient protective immune responses? Nat. Med. 11(Suppl. 4), S54-S62 (2005).
2. Doherty PC, Turner SJ, Webby RG, Thomas PG. Influenza and the challenge for immunology. Nat. Immunol. 7(5), 449-455 (2006).
3. McMichael AJ. HIV vaccines. Annu. Rev. Immunol. 24, 227-255 (2006).
4. Metkar SS, Wang B, Aguilar-Santelises M et al. Cytotoxic cell granule-mediated apoptosis: perforin delivers granzyme B-serglycin complexes into target cells without plasma membrane pore formation. Immunity 16(3), 417-428 (2002).
5. Hammarlund E, Lewis MW, Hansen SG et al. Duration of antiviral immunity after smallpox vaccination. Nat. Med. 9(9), 1131-1137 (2003). • Demonstrates that cellular immunity in humans can persist for decades following pathogen exposure.
6. Naniche D, Garenne M, Rae C et al. Decrease in measles virus-specific CD4 T cell memory in vaccinated subjects. J. Infect. Dis. 190(8), 1387-1395 (2004).
7. Barouch DH, Nabel GJ. Adenovirus vector-based vaccines for human immunodeficiency virus type 1. Hum. Gene Ther. 16(2), 149-156 (2005).
8. Capone S, Meola A, Ercole BB et al. A novel adenovirus type 6 (Ad6)-based hepatitis C virus vector that overcomes preexisting anti-Ad5 immunity and induces potent and broad cellular immune responses in rhesus macaques. J. Virol. 80(4), 1688-1699 (2006).
9. Xing Z, Santosuosso M, McCormick S et al. Recent advances in the development of adenovirus- and poxvirus-vectored tuberculosis vaccines. Curr. Gene Ther. 5(5), 485-492 (2005).
10. Gao W, Soloff AC, Lu X et al. Protection of mice and poultry from lethal H5N1 avian influenza virus through adenovirus-based immunization. J. Virol. 80(4), 1959-1964 (2006).
11. Li S, Locke E, Bruder J et al. Viral vectors for malaria vaccine development. Vaccine 25(14), 2567-2574 (2006).
12. Gallo P, Dharmapuri S, Cipriani B, Monaci P. Adenovirus as vehicle for anticancer genetic immunotherapy. Gene Ther. 12(Suppl. 1), S84-S91 (2005).
13. Lane C, Leitch J, Tan X, Hadjati J, Bramson JL, Wan Y. Vaccination-induced autoimmune vitiligo is a consequence of secondary trauma to the skin. Cancer Res. 64(4), 1509-1514 (2004).
14. Van Kampen KR, Shi Z, Gao P et al. Safety and immunogenicity of adenovirus-vectored nasal and epicutaneous influenza vaccines in humans. Vaccine 23(8), 1029-1036 (2005).
15. Catanzaro AT, Koup RA, Roederer M et al. Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector. J. Infect. Dis. 194(12), 1638-1649 (2006). •• Reports on one of the first clinical trials with direct injection of adenovirus vaccines for HIV. Demonstrates that immunization with human type 5 adenovirus can elicit T-cell and antibody responses in humans.
16. Kaech SM, Wherry EJ, Ahmed R. Effector and memory T-cell differentiation: implications for vaccine development. Nat. Rev. Immunol. 2(4), 251-262 (2002).
17. Rowe WP, Huebner RJ, Gilmore LK, Parrott RH, Ward TG. Isolation of a cytopathogenic agent from human adenoids undergoing spontaneous degeneration in tissue culture. Proc. Soc. Exp. Biol. Med. 84(3), 570-573 (1953).
18. Hilleman MR, Werner JH. Recovery of new agent from patients with acute respiratory illness. Proc. Soc. Exp. Biol. Med. 85(1), 183-188 (1954).
19. Shenk TE. Adenoviridae: the viruses and their replication. In: Fields Virology (4th Edition). Knipe DM, Howley PM (Eds). Lippincott Williams & Wilkins, PA, USA 2265-2300 (2001).
20. Ghosh-Choudhury G, Haj-Ahmad Y, Graham FL. Protein IX, a minor component of the human adenovirus capsid, is essential for the packaging of full length genomes. EMBO J. 6(6), 1733-1739 (1987).
21. Ng P, Parks RJ, Cummings DT, Evelegh CM, Graham FL. An enhanced system for construction of adenoviral vectors by the two-plasmid rescue method. Hum. Gene Ther. 11(5), 693-699 (2000).
22. Russell WC. Update on adenovirus and its vectors. J. Gen. Virol. 81(Pt 11), 2573-2604 (2000).
23. Spergel JM, Hsu W, Akira S, Thimmappaya B, Kishimoto T, Chen-Kiang S. NF-IL6, a member of the C/EBP family, regulates E1A-responsive promoters in the absence of E1A. J. Virol. 66(2), 1021-1030 (1992).
24. Graham FL, Smiley J, Russell WC, Nairn R. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J. Gen. Virol. 36(1), 59-74 (1977).
25. Fallaux FJ, Bout A, van der Velde I et al. New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication-competent adenoviruses. Hum. Gene Ther. 9(13), 1909-1917 (1998).
26. Song W, Kong HL, Traktman P, Crystal RG. Cytotoxic T lymphocyte responses to proteins encoded by heterologous transgenes transferred in vivo by adenoviral vectors. Hum. Gene Ther. 8(10), 1207-1217 (1997).
27. Yang Y, Jooss KU, Su Q, Ertl HC, Wilson JM. Immune responses to viral antigens versus transgene product in the elimination of recombinant adenovirus-infected hepatocytes in vivo. Gene Ther. 3(2), 137-144 (1996).
28. Yang Y, Li Q, Ertl HC, Wilson JM. Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses. J. Virol. 69(4), 2004-2015 (1995).
29. Tatsis N, Ertl HC. Adenoviruses as vaccine vectors. Mol. Ther. 10(4), 616-629 (2004).
30. + T-cell response through radioresistant antigen-presenting cells, making these vectors highly suitable for use in cancer patients who are often rendered leukopenic by their treatment schedules.
31. + T cell response elicited by recombinant adenovirus vaccines. Mol. Ther. 15(5), 997-1006 (2007).
32. + T-cell response following adenovirus vaccination. J. Virol. 77(24), 13407-13411 (2003).
33. + T-cell population produced by immunization with type 5 adenovirus.
34. Wherry EJ, Ahmed R. Memory CD8 T-cell differentiation during viral infection. J. Virol. 78(11), 5535-5545 (2004).
35. Sallusto F, Geginat J, Lanzavecchia A. Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu. Rev. Immunol. 22, 745-763 (2004).
36. Lefrancois L, Masopust D. T cell immunity in lymphoid and non-lymphoid tissues. Curr. Opin. Immunol. 14(4), 503-508 (2002).
37. + T cell subsets identified by expression of IL-7 receptor α and CD62L. J. Immunol. 175(7), 4686-4696 (2005).
38. + memory T cell subsets. Proc. Natl Acad. Sci. USA 101(15), 5610-5615 (2004).
39. Wherry EJ, Teichgraber V, Becker TC et al. Lineage relationship and protective immunity of memory CD8 T cell subsets. Nat. Immunol. 4(3), 225-234 (2003).
40. Hu H, Huston G, Duso D, Lepak N, Roman E, Swain SL. CD4(+) T cell effectors can become memory cells with high efficiency and without further division. Nat. Immunol. 2(8), 705-710 (2001).
41. Lanzavecchia A, Sallusto F. Progressive differentiation and selection of the fittest in the immune response. Nat. Rev. Immunol. 2(12), 982-987 (2002).
42. + central memory T cells into protective Listeria-specific effector memory T cells. Eur. J. Immunol. 36(6), 1453-1464 (2006).
43. + T cell lineage commitment. Nat. Immunol. 6(8), 793-799 (2005).
44. Baron V, Bouneaud C, Cumano A et al. The repertoires of circulating human CD8(+) central and effector memory T cell subsets are largely distinct. Immunity 18(2), 193-204 (2003).
45. Zaph C, Uzonna J, Beverley SM, Scott P. Central memory T cells mediate long-term immunity to Leishmania major in the absence of persistent parasites. Nat. Med. 10(10), 1104-1110 (2004).
46. Zammit DJ, Cauley LS, Pham QM, Lefrancois L. Dendritic cells maximize the memory CD8 T cell response to infection. Immunity 22(5), 561-570 (2005).
47. + T cells and antiviral protection. J. Immunol. 175(7), 4677-4685 (2005).
48. Jackson SS, Schmitz JE, Kuroda MJ et al. Evaluation of CD62L expression as a marker for vaccine-elicited memory cytotoxic T lymphocytes. Immunology 116(4), 443-453 (2005).
49. + T cells confer superior antitumor immunity compared with effector memory T cells. Proc. Natl Acad. Sci. USA 102(27), 9571-9576 (2005).
50. + T cell induction, is dependent on type I IFN signaling during vaccination with adenovirus vectors. J. Immunol. 175(9), 6032-6041 (2005).
51. Santra S, Seaman MS, Xu L et al. Replication-defective adenovirus serotype 5 vectors elicit durable cellular and humoral immune responses in nonhuman primates. J. Virol. 79(10), 6516-6522 (2005).
52. Casimiro DR, Chen L, Fu TM et al. Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene. J. Virol. 77(11), 6305-6313 (2003).
53. Thorner AR, Lemckert AA, Goudsmit J et al. Immunogenicity of heterologous recombinant adenovirus prime-boost vaccine regimens is enhanced by circumventing vector cross-reactivity. J. Virol. 80(24), 12009-12016 (2006).
54. Wong P, Pamer EG. Feedback regulation of pathogen-specific T cell priming. Immunity 18(4), 499-511 (2003).
55. + T cell responses during a persistent virus infection. J. Immunol. 174(12), 7950-7960 (2005).
56. Obar JJ, Fuse S, Leung EK, Bellfy SC, Usherwood EJ. Gammaherpesvirus persistence alters key CD8 T-cell memory characteristics and enhances antiviral protection. J. Virol. 80(17), 8303-8315 (2006).
57. Wherry EJ, Ahmed R. Memory CD8 T-cell differentiation during viral infection. J. Virol. 78(11), 5535-5545 (2004).
58. Masopust D, Ha SJ, Vezys V, Ahmed R. Stimulation history dictates memory CD8 T cell phenotype: implications for prime-boost vaccination. J. Immunol. 177(2), 831-839 (2006).
59. + T-cell memory in a model of localized transient infection. Immunol. Rev. 211, 133-145 (2006).
60. Pascual DW, Walters N, Hillemeyer P. Repeated intratracheal instillations of nonreplicating adenovirus 2 vector attenuate CTL responses and IFN-γ production. J. Immunol. 160(9), 4465-4472 (1998).
61. Krebs P, Scandella E, Odermatt B, Ludewig B. Rapid functional exhaustion and deletion of CTL following immunization with recombinant adenovirus. J. Immunol. 174(8), 4559-4566 (2005).
62. + T cell response. Immunity 25(1), 19-29 (2006).
63. Muruve DA. The innate immune response to adenovirus vectors. Hum. Gene Ther. 15(12), 1157-1166 (2004).
64. Turner DL, Cauley LS, Khanna KM, Lefrancois L. Persistent antigen presentation after acute vesicular stomatitis virus infection. J. Virol. 81(4), 2039-2046 (2007).
65. Zammit DJ, Turner DL, Klonowski KD, Lefrancois L, Cauley LS. Residual antigen presentation after influenza virus infection affects CD8 T cell activation and migration. Immunity 24(4), 439-449 (2006).
66. Jelley-Gibbs DM, Brown DM, Dibble JP, Haynes L, Eaton SM, Swain SL. Unexpected prolonged presentation of influenza antigens promotes CD4 T cell memory generation. J. Exp. Med. 202(5), 697-706 (2005).
67. Bevan MJ. Helping the CD8(+) T-cell response. Nat. Rev. Immunol. 4(8), 595-602 (2004).
68. Behrens G, Li M, Smith CM et al. Helper T cells, dendritic cells and CTL immunity. Immunol. Cell. Biol. 82(1), 84-90 (2004).
69. Smith CM, Wilson NS, Waithman J et al. Cognate CD4(+) T cell licensing of dendritic cells in CD8(+) T cell immunity. Nat. Immunol. 5(11), 1143-1148 (2004).
70. + T lymphocytes. Nature 421(6925), 852-856 (2003).
71. Shedlock DJ, Shen H. Requirement for CD4 T cell help in generating functional CD8 T cell memory. Science 300(5617), 337-339 (2003).
72. + memory T cells. Immunol. Rev. 211, 146-153 (2006).
73. Marzo AL, Vezys V, Klonowski KD et al. Fully functional memory CD8 T cells in the absence of CD4 T cells. J. Immunol. 173(2), 969-975 (2004).
74. Jooss K, Yang Y, Fisher KJ, Wilson JM. Transduction of dendritic cells by DNA viral vectors directs the immune response to transgene products in muscle fibers. J. Virol. 72(5), 4212-4223 (1998).
75. Mercier S, Gahery-Segard H, Monteil M et al. Distinct roles of adenovirus vector-transduced dendritic cells, myoblasts, and endothelial cells in mediating an immune response against a transgene product. J. Virol. 76(6), 2899-2911 (2002).
76. Sarukhan A, Camugli S, Gjata B, von Boehmer H, Danos O, Jooss K. Successful interference with cellular immune responses to immunogenic proteins encoded by recombinant viral vectors. J. Virol. 75(1), 269-277 (2001).
77. Zhang Y, Chirmule N, Gao GP et al. Acute cytokine response to systemic adenoviral vectors in mice is mediated by dendritic cells and macrophages. Mol. Ther. 3(5 Pt 1), 697-707 (2001).
78. + dendritic cells but not by Langerhans cells. Science 301(5641), 1925-1928 (2003).
79. Iwasaki A, Torres CA, Ohashi PS, Robinson HL, Barber BH. The dominant role of bone marrow-derived cells in CTL induction following plasmid DNA immunization at different sites. J. Immunol. 159(1), 11-14 (1997).
80. Lenz LL, Butz EA, Bevan MJ. Requirements for bone marrow-derived antigen-presenting cells in priming cytotoxic T cell responses to intracellular pathogens. J. Exp. Med. 192(8), 1135-1142 (2000).
81. Sigal LJ, Crotty S, Andino R, Rock KL. Cytotoxic T-cell immunity to virus-infected non-haematopoietic cells requires presentation of exogenous antigen [see comments]. Nature 398(6722), 77-80 (1999).
82. Sigal LJ, Rock KL. Bone marrow-derived antigen-presenting cells are required for the generation of cytotoxic T lymphocyte responses to viruses and use transporter associated with antigen presentation (TAP)-dependent and -independent pathways of antigen presentation. J. Exp. Med. 192(8), 1143-1150 (2000).
83. Belz GT, Wilson NS, Smith CM, Mount AM, Carbone FR, Heath WR. Bone marrow-derived cells expand memory CD8(+) T cells in response to viral infections of the lung and skin. Eur. J. Immunol. 36(2), 327-335 (2006).
84. Merad M, Manz MG, Karsunky H et al. Langerhans cells renew in the skin throughout life under steady-state conditions. Nat. Immunol. 3(12), 1135-1141 (2002).
85. Kundig TM, Bachmann MF, DiPaolo C et al. Fibroblasts as efficient antigen-presenting cells in lymphoid organs. Science 268(5215), 1343-1347 (1995).
86. Bangari DS, Mittal SK. Development of nonhuman adenoviruses as vaccine vectors. Vaccine 24(7), 849-62 (2006).
87. + T lymphocytes both contribute to immunity to adenovirus serotype 5 vaccine vectors. J. Virol. 78(6), 2666-2673 (2004).
88. Leopold PL, Wendland RL, Vincent T, Crystal RG. Neutralized adenovirus-immune complexes can mediate effective gene transfer via an Fc receptor-dependent infection pathway. J. Virol. 80(20), 10237-10247 (2006).
89. Gao W, Robbins PD, Gambotto A. Human adenovirus type 35: nucleotide sequence and vector development. Gene Ther. 10(23), 1941-1949 (2003).
90. Stone D, Ni S, Li ZY et al. Development and assessment of human adenovirus type 11 as a gene transfer vector. J. Virol. 79(8), 5090-5104 (2005).
91. Shiver JW, Emini EA. Recent advances in the development of HIV-1 vaccines using replication-incompetent adenovirus vectors. Annu. Rev. Med. 55, 355-372 (2004).
92. Rich DP, Couture LA, Cardoza LM et al. Development and analysis of recombinant adenoviruses for gene therapy of cystic fibrosis. Hum. Gene Ther. 4(4), 461-476 (1993).
93. Nan X, Peng B, Hahn TW et al. Development of an Ad7 cosmid system and generation of an Ad7δE1δE3HIV(MN) env/rev recombinant virus. Gene Ther. 10(4), 326-336 (2003).
94. Michou AI, Lehrmann H, Saltik M, Cotten M. Mutational analysis of the avian adenovirus CELO, which provides a basis for gene delivery vectors. J. Virol. 73(2), 1399-1410 (1999).
95. Hofmann C, Loser P, Cichon G, Arnold W, Both GW, Strauss M. Ovine adenovirus vectors overcome preexisting humoral immunity against human adenoviruses in vivo. J. Virol. 73(8), 6930-6936 (1999).
96. Kremer EJ, Boutin S, Chillon M, Danos O. Canine adenovirus vectors: an alternative for adenovirus-mediated gene transfer. J. Virol. 74(1), 505-512 (2000).
97. Reddy PS, Idamakanti N, Babiuk LA, Mehtali M, Tikoo SK. Porcine adenovirus-3 as a helper-dependent expression vector. J. Gen. Virol. 80(Pt 11), 2909-2916 (1999).
98. Reddy PS, Idamakanti N, Chen Y et al. Replication-defective bovine adenovirus type 3 as an expression vector. J. Virol. 73(11), 9137-9144 (1999).
99. Tatsis N, Tesema L, Robinson ER et al. Chimpanzee-origin adenovirus vectors as vaccine carriers. Gene Ther. 13(5), 421-429 (2006).
100. Wickham TJ, Mathias P, Cheresh DA, Nemerow GR. Integrins α v β 3 and α v β 5 promote adenovirus internalization but not virus attachment. Cell 73(2), 309-319 (1993).
101. Zhang Y, Bergelson JM. Adenovirus receptors. J. Virol. 79(19), 12125-12131 (2005).
102. Sumida SM, Truitt DM, Lemckert AA et al. Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein. J. Immunol. 174(11), 7179-7185 (2005). •• Shows that the key neutralizing targets in vivo are found in the hexon protein as opposed to the fiber protein that is a target for neutralizing antibodies in vitro.
103. Roberts DM, Nanda A, Havenga MJ et al. Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity. Nature 441(7090), 239-243 (2006).
104. Bergelson JM, Cunningham JA, Droguett G et al. Isolation of a common receptor for coxsackie B viruses and adenoviruses 2 and 5. Science 275(5304), 1320-1323 (1997).
105. Roelvink PW, Lizonova A, Lee JG et al. The coxsackievirus- adenovirus receptor protein can function as a cellular attachment protein for adenovirus serotypes from subgroups A, C, D, E, and F. J. Virol. 72(10), 7909-7915 (1998).
106. Dechecchi MC, Melotti P, Bonizzato A, Santacatterina M, Chilosi M, Cabrini G. Heparan sulfate glycosaminoglycans are receptors sufficient to mediate the initial binding of adenovirus types 2 and 5. J. Virol. 75(18), 8772-8780 (2001).
107. Arnberg N, Edlund K, Kidd AH, Wadell G. Adenovirus type 37 uses sialic acid as a cellular receptor. J. Virol. 74(1), 42-48 (2000).
108. Arnberg N, Kidd AH, Edlund K, Olfat F, Wadell G. Initial interactions of subgenus D adenoviruses with A549 cellular receptors: sialic acid versus α(v) integrins. J. Virol. 74(16), 7691-7693 (2000).
109. Ni S, Bernt K, Gaggar A, Li ZY, Kiem HP, Lieber A. Evaluation of biodistribution and safety of adenovirus vectors containing group B fibers after intravenous injection into baboons. Hum. Gene Ther. 16(6), 664-677 (2005).
110. Verhaagh S, de Jong E, Goudsmit J et al. Human CD46-transgenic mice in studies involving replication-incompetent adenoviral type 35 vectors. J. Gen. Virol. 87(Pt 2), 255-265 (2006).
111. DiPaolo N, Ni S, Gaggar A et al. Evaluation of adenovirus vectors containing serotype 35 fibers for vaccination. Mol. Ther. 13(4), 756-765 (2006).
112. Tamanini A, Nicolis E, Bonizzato A et al. Interaction of adenovirus type 5 fiber with the coxsackievirus and adenovirus receptor activates inflammatory response in human respiratory cells. J. Virol. 80(22), 11241-11254 (2006).
113. Iacobelli-Martinez M, Nepomuceno RR, Connolly J, Nemerow GR. CD46-utilizing adenoviruses inhibit C/EBPβ-dependent expression of proinflammatory cytokines. J. Virol. 79(17), 11259-11268 (2005).
114. Iacobelli-Martinez M, Nemerow GR. Preferential activation of Toll-like receptor nine by CD46-utilizing adenoviruses. J. Virol. 81(3), 1305-1312 (2007).
115. + cells with CD3 and CD46 induces a T-regulatory cell 1 phenotype. Nature 421(6921), 388-392 (2003).
116. Hensley SE, Cun AS, Giles-Davis W et al. Type I interferon inhibits antibody responses induced by a chimpanzee adenovirus vector. Mol. Ther. 15(2), 393-403 (2007). • Demonstrates that vector serotype affects not only tropism but also host defense. In this case, the heightened ability of a chimpanzee adenovirus to elicit interferon production reduced its ability to elicit antibodies relative to a human type 5 adenovirus.
117. Sullivan NJ, Geisbert TW, Geisbert JB et al. Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates. Nature 424(6949), 681-684 (2003).
118. Siemens DR, Elzey BD, Lubaroff DM et al. Cutting edge: restoration of the ability to generate CTL in mice immune to adenovirus by delivery of virus in a collagen-based matrix. J. Immunol. 166(2), 731-735 (2001).